AvalehtAVDL • NASDAQ
add
Avadel Pharmaceuticals PLC
11,66 $
Pärast sulgemist:(0,00%)0,00
11,66 $
Suletud: 22. nov, 20:00:00 GMT −5 · USD · NASDAQ · Välistus
Viimane sulgemishind
11,66 $
Tänane vahemik
11,53 $ - 12,22 $
Aasta vahemik
10,41 $ - 19,09 $
Turuväärtus
1,12 mld USD
Keskmine maht
1,35 mln
P/E suhe
-
Dividendimäär
-
Põhibörs
NASDAQ
Uudised
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
| (USD) | sept 2024info | Y/Y muutus |
|---|---|---|
Käive | 50,02 mln | 613,22% |
Põhitegevusega seonduv kulu | 44,20 mln | 5,21% |
Puhastulu | −2,62 mln | 92,76% |
Puhaskasumimarginaal | −5,25 | 98,98% |
Puhaskasum aktsia kohta | −0,03 | 92,68% |
EBITDA | 708,00 tuh | 102,05% |
Tõhus maksumäär | −3,47% | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
| (USD) | sept 2024info | Y/Y muutus |
|---|---|---|
Sularaha ja lühiajalised investeeringud | 65,81 mln | −57,04% |
Kogu vara | 158,25 mln | −22,08% |
Kõik kohustused | 83,59 mln | −10,07% |
Kogu omakapital | 74,66 mln | — |
Emiteeritud aktsiate arv | 96,36 mln | — |
Hinna ja väärtuse suhe P/B | 14,95 | — |
Varade tasuvus | −0,52% | — |
Kapitali tasuvus | −0,73% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
| (USD) | sept 2024info | Y/Y muutus |
|---|---|---|
Puhastulu | −2,62 mln | 92,76% |
Põhitegevuse rahakäive | −6,89 mln | 81,98% |
Investeeringute raha | 4,93 mln | −49,80% |
Finantseerimise raha | 1,18 mln | −96,14% |
Raha ja raha ekvivalentide muutus | −265,00 tuh | −114,51% |
Tasuta rahavoog | −9,99 mln | 64,96% |
Teave
Avadel Pharmaceuticals plc, is a specialty pharmaceutical company. Avadel markets products in the hospital and primary care spaces. The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France.
The company was founded as Flamel Technologies SA in Lyon, France in 1990.
The company acquired Éclat Pharmaceuticals of St. Louis, Missouri in March 2012.
On 8 February 2016, the company acquired FSC Holdings, LLC, which included its wholly owned subsidiaries FSC Pediatrics, Inc., FSC Therapeutics, LLC, and FSC Laboratories, Inc.
On 3 January 2017, Flamel, Éclat, and FCS Pediatrics became Avadel Pharmaceuticals plc after the Company completed a cross-border merger from France to Ireland.
In 2019, Mike Anderson, CEO of Avadel Pharmaceuticals has resigned, and Gregory Divis, COO of the company was appointed as his temporary successor. Meanwhile, Craig Stapleton, chairman of the Dublin-headquartered Avadel, has also stepped down. That same year, the company filed for Chapter 11 bankruptcy.
In May 2023, Avadel Pharmaceuticals received FDA approval for Lumryz, an extended-release oral suspension of sodium oxybate. Wikipedia
Tegevjuht
Asutatud
1990
Veebisait
Töötajate arv
154
